Lithium ameliorates tubule-interstitial injury through activation of the mTORC2/protein kinase B pathway

PLoS One. 2019 Apr 19;14(4):e0215871. doi: 10.1371/journal.pone.0215871. eCollection 2019.

Abstract

Tubule-interstitial injury (TII) is a critical step in the progression of renal disease. It has been proposed that changes in proximal tubule (PT) albumin endocytosis plays an important role in the development of TII. Some reports have shown protective effects of lithium on kidney injury animal models that was correlated to proteinuria. We tested the hypothesis that lithium treatment ameliorates the development of TII due to changes in albumin endocytosis. Two experimental models were used: (1) TII induced by albumin overload in an animal model; (2) LLC-PK1 cells, a PT cell line. Lithium treatment ameliorates TII induced by albumin overload measured by (1) proteinuria; (2) collagen deposition; (3) area of tubule-interstitial space, and (4) macrophage infiltration. Lithium treatment increased mTORC2 activity leading to the phosphorylation of protein kinase B (PKB) at Ser473 and its activation. This mechanism enhanced albumin endocytosis in PT cells, which decreased the proteinuria observed in TII induced by albumin overload. This effect did not involve changes in the expression of megalin, a PT albumin receptor. In addition, activation of this pathway decreased apoptosis in LLC-PK1 cells, a PT cell line, induced by higher albumin concentration, similar to that found in pathophysiologic conditions. Our results indicate that the protective role of lithium treatment on TII induced by albumin overload involves an increase in PT albumin endocytosis due to activation of the mTORC2/PKB pathway. These results open new possibilities in understanding the effects of lithium on the progression of renal disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins / metabolism
  • Animals
  • Apoptosis / drug effects
  • Cell Line
  • Cell Movement / drug effects
  • Endocytosis / drug effects
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Epithelial Cells / pathology
  • Gene Expression Regulation
  • Humans
  • Kidney Tubules, Proximal / drug effects*
  • Kidney Tubules, Proximal / injuries
  • Kidney Tubules, Proximal / metabolism
  • Lithium Carbonate / pharmacology*
  • Low Density Lipoprotein Receptor-Related Protein-2 / genetics
  • Low Density Lipoprotein Receptor-Related Protein-2 / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • Mechanistic Target of Rapamycin Complex 2 / agonists
  • Mechanistic Target of Rapamycin Complex 2 / genetics*
  • Mechanistic Target of Rapamycin Complex 2 / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Protective Agents / pharmacology*
  • Proteinuria / drug therapy*
  • Proteinuria / metabolism
  • Proteinuria / physiopathology
  • Proto-Oncogene Proteins c-akt / agonists
  • Proto-Oncogene Proteins c-akt / genetics*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction / drug effects

Substances

  • Albumins
  • Low Density Lipoprotein Receptor-Related Protein-2
  • Lrp2 protein, mouse
  • Protective Agents
  • Lithium Carbonate
  • Mechanistic Target of Rapamycin Complex 2
  • Proto-Oncogene Proteins c-akt

Grants and funding

This work was supported by grants from the following Brazilian agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (www.cnpq.br): 304682/2015-2 (AASP); 303793/2015-5 (CCN); and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro–FAPERJ (www.faperj.br): E-26/202.950/2016 (AASP); E-26/202.833/2017 (CCN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.